104 related articles for article (PubMed ID: 17658249)
1. Effects of formoterol on exercise tolerance in severely disabled patients with COPD.
Neder JA; Fuld JP; Overend T; Thirlwell J; Carter R; Stevenson R; Ward SA
Respir Med; 2007 Oct; 101(10):2056-64. PubMed ID: 17658249
[TBL] [Abstract][Full Text] [Related]
2. Effects of tiotropium and formoterol on dynamic hyperinflation and exercise endurance in COPD.
Berton DC; Reis M; Siqueira AC; Barroco AC; Takara LS; Bravo DM; Andreoni S; Neder JA
Respir Med; 2010 Sep; 104(9):1288-96. PubMed ID: 20580216
[TBL] [Abstract][Full Text] [Related]
3. Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD.
Worth H; Förster K; Eriksson G; Nihlén U; Peterson S; Magnussen H
Respir Med; 2010 Oct; 104(10):1450-9. PubMed ID: 20692140
[TBL] [Abstract][Full Text] [Related]
4. Is there any difference between effects of ipratropium bromide and formoterol on exercise capacity in moderate COPD patients?
Akkoca Yildiz O; Onen ZP; Demir G; Eriş Gülbay B; Saryal S; Karabiyikoğlu G
Tuberk Toraks; 2006; 54(2):105-13. PubMed ID: 16924565
[TBL] [Abstract][Full Text] [Related]
5. [The influence of treatment with formoterol, formoterol with tiotropium, formoterol with inhaled glucocorticosteroid and tiotropium on lung functions, tolerance of exercise and simple, morning everyday activities in patients with chronic obstructive pulmonary disease (COPD)].
Szmidt M
Pneumonol Alergol Pol; 2012; 80(3):255-62. PubMed ID: 22562275
[TBL] [Abstract][Full Text] [Related]
6. Inhaled fentanyl citrate improves exercise endurance during high-intensity constant work rate cycle exercise in chronic obstructive pulmonary disease.
Jensen D; Alsuhail A; Viola R; Dudgeon DJ; Webb KA; O'Donnell DE
J Pain Symptom Manage; 2012 Apr; 43(4):706-19. PubMed ID: 22168961
[TBL] [Abstract][Full Text] [Related]
7. Lung deposition and efficacy of inhaled formoterol in patients with moderate to severe COPD.
Derom E; Strandgården K; Schelfhout V; Borgström L; Pauwels R
Respir Med; 2007 Sep; 101(9):1931-41. PubMed ID: 17544264
[TBL] [Abstract][Full Text] [Related]
8. Inhaled formoterol versus ipratropium bromide in chronic obstructive pulmonary disease.
Chhabra SK; Vijayan VK; Vasu T
Indian J Chest Dis Allied Sci; 2006; 48(2):97-102. PubMed ID: 16696522
[TBL] [Abstract][Full Text] [Related]
9. Addition of tiotropium to formoterol improves inspiratory muscle strength after exercise in COPD.
Canto ND; Ribeiro JP; Neder JA; Chiappa GR
Respir Med; 2012 Oct; 106(10):1404-12. PubMed ID: 22748747
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of acute bronchodilator reversibility in patients with symptoms of GOLD stage I COPD.
O'Donnell DE; Laveneziana P; Ora J; Webb KA; Lam YM; Ofir D
Thorax; 2009 Mar; 64(3):216-23. PubMed ID: 19052054
[TBL] [Abstract][Full Text] [Related]
11. Acute and short-term effect of an extra dose of formoterol in COPD patients.
Studart FS; Izbicki M; Nery LE; Oliveira LV; Donner CF; Jardim JR; Nascimento OA
Respir Med; 2012 Jun; 106(6):853-60. PubMed ID: 22336262
[TBL] [Abstract][Full Text] [Related]
12. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial.
Tashkin DP; Littner M; Andrews CP; Tomlinson L; Rinehart M; Denis-Mize K
Respir Med; 2008 Apr; 102(4):479-87. PubMed ID: 18258423
[TBL] [Abstract][Full Text] [Related]
13. Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD.
Beeh KM; Wagner F; Khindri S; Drollmann AF
COPD; 2011 Oct; 8(5):340-5. PubMed ID: 21793716
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of dyspnoea relief and improved exercise endurance after furosemide inhalation in COPD.
Jensen D; Amjadi K; Harris-McAllister V; Webb KA; O'Donnell DE
Thorax; 2008 Jul; 63(7):606-13. PubMed ID: 18250181
[TBL] [Abstract][Full Text] [Related]
15. Effects of formoterol and salmeterol on resting inspiratory capacity in COPD patients with poor FEV(1) reversibility.
Bouros D; Kottakis J; Le Gros V; Overend T; Della Cioppa G; Siafakas N
Curr Med Res Opin; 2004 May; 20(5):581-6. PubMed ID: 15140323
[TBL] [Abstract][Full Text] [Related]
16. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
Lindberg A; Szalai Z; Pullerits T; Radeczky E
Respirology; 2007 Sep; 12(5):732-9. PubMed ID: 17875063
[TBL] [Abstract][Full Text] [Related]
17. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study.
Vogelmeier C; Kardos P; Harari S; Gans SJ; Stenglein S; Thirlwell J
Respir Med; 2008 Nov; 102(11):1511-20. PubMed ID: 18804362
[TBL] [Abstract][Full Text] [Related]
18. Anti-inflammatory effects of combined budesonide/formoterol in COPD exacerbations.
Bathoorn E; Liesker JJ; Postma DS; Boorsma M; Bondesson E; Koëter GH; Kauffman HF; van Oosterhout AJ; Kerstjens HA
COPD; 2008 Oct; 5(5):282-90. PubMed ID: 18972276
[TBL] [Abstract][Full Text] [Related]
19. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
[TBL] [Abstract][Full Text] [Related]
20. Modulation of operational lung volumes with the use of salbutamol in COPD patients accomplishing upper limbs exercise tests.
Porto EF; Castro AA; Nascimento O; Oliveira RC; Cardoso F; Jardim JR
Respir Med; 2009 Feb; 103(2):251-7. PubMed ID: 18930646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
